Local therapies for inflammatory eye disease in translation: Past, present and future

BMC Ophthalmology

Volumn 13, Issue 1, 2013, Pages

  Tempest Roe, Shenzhen ^a   Joshi, Lavnish ^a,b,c   Dick, Andrew D ^c,d,e   Taylor, Simon Rj ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d MOORFIELDS EYE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DRUG ANTAGONISM; EYE DISEASE; HUMAN; UVEITIS;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; EYE DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 84881070077     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-13-39     Document Type: Review

References (105)

1. International Uveitis Study Group (IUSG): clinical classification of uveitis. Deschenes J, Murray PI, Rao NA, Nussenblatt RB, Ocul Immunol Inflamm 2008 16 1 1 2 18379933 (Pubitemid 351480322)
2. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Jabs DA, Nussenblatt RB, Rosenbaum JT, Am J Ophthalmol 2005 140 3 509 516 16196117 (Pubitemid 41224845)
3. What is new HLA-B27 acute anterior uveitis? Wakefield D, Chang JH, Amjadi S, Maconochie Z, Abu El-Asrar A, McCluskey P, Ocul Immunol Inflamm 2011 19 2 139 144 10.3109/09273948.2010.542269 21428757
4. New developments in corticosteroid therapy for uveitis. Taylor SR, Isa H, Joshi L, Lightman S, Ophthalmologica 2010 224 Suppl 1 46 53 20714181
5. Review and update of intraocular therapy in noninfectious uveitis. Sallam A, Taylor SR, Lightman S, Curr Opin Ophthalmol 2011 22 6 517 522 10.1097/ICU.0b013e32834bbd68 21897242
6. Advances in the diagnosis and immunotherapy for ocular inflammatory disease. Yeh S, Faia LJ, Nussenblatt RB, Semin Immunopathol 2008 30 2 145 164 10.1007/s00281-008-0109-4 18320151
7. Difluprednate for inflammatory eye disorders. Mulki L, Foster CS, Drugs Today (Barc) 2011 47 5 327 333
8. Efficacy and safety of 1% rimexolone versus 1% prednisolone acetate in the treatment of anterior uveitis-a randomized triple masked study. Biswas J, Ganeshbabu TM, Raghavendran SR, Raizada S, Mondkar SV, Madhavan HN, Int Ophthalmol 2004 25 3 147 153 10.1007/s10792-004-5195-2 15847313
9. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group, Am J Ophthalmol 1999 127 5 537 544 10334346
10. Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance. Awan MA, Agarwal PK, Watson DG, McGhee CN, Dutton GN, Br J Ophthalmol 2009 93 6 708 713 10.1136/bjo.2008.154906 19293163
11. Long-term, multicenter evaluation of subconjunctival injection of triamcinolone for non-necrotizing, noninfectious anterior scleritis. Sohn EH, Wang R, Read R, Roufas A, Teo L, Moorthy R, Albini T, Vasconcelos-Santos DV, Dustin LD, Zamir E, et al. Ophthalmology 2011 118 10 1932 1937 10.1016/j.ophtha.2011.02.043 21708408
12. Nonsteroidal anti-inflammatory drugs in ophthalmology. Kim SJ, Flach AJ, Jampol LM, Surv Ophthalmol 2010 55 2 108 133 10.1016/j.survophthal.2009.07.005 20159228
13. A systematic review of the association of diabetic retinopathy and cognitive impairment in people with Type 2 diabetes. Crosby-Nwaobi R, Sivaprasad S, Forbes A, Diabetes research and clinical practice 2012 96 2 101 110 10.1016/j.diabres.2011.11.010 22154373
14. Local cyclosporine therapy for experimental autoimmune uveitis in rats. Nussenblatt RB, Dinning WJ, Fujikawa LS, Chan CC, Palestine AG, Arch Ophthalmol 1985 103 10 1559 1562 10.1001/archopht.1985.01050100135035 3901986 (Pubitemid 15240748)
15. Topical application of ciclosporin ophthalmic solution containing alpha-cyclodextrin in experimental uveitis. Sasamoto Y, Hirose S, Ohno S, Onoe K, Matsuda H, Ophthalmologica 1991 203 3 118 125 10.1159/000310237 1775299
16. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. Nguyen QD, Ibrahim MA, Watters A, Bittencourt M, Yohannan J, Sepah YJ, Dunn JP, Naor J, Shams N, Shaikh O, et al. J Ophthalmic Inflamm Infect 2013 3 1 32 10.1186/1869-5760-3-32 23514595
17. Developments in the treatment of uveitis. Lightman S, Kok H, Expert Opin Investig Drugs 2002 11 1 59 67 10.1517/13543784.11.1.59 11772321 (Pubitemid 34048618)
18. Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Ferrante P, Ramsey A, Bunce C, Lightman S, Clin Experiment Ophthalmol 2004 32 6 563 568 10.1111/j.1442-9071.2004.00902.x 15575824 (Pubitemid 40074099)
19. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Helm CJ, Holland GN, Am J Ophthalmol 1995 120 1 55 64 7611330
20. Comparison of orbital floor triamcinolone acetonide and oral prednisolone for cataract surgery management in patients with non-infectious uveitis. Roesel M, Heinz C, Koch JM, Heiligenhaus A, Graefes Arch Clin Exp Ophthalmol 2010 248 5 715 720 10.1007/s00417-009-1269-1 20082200
21. A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Gaudio PA, Ocul Immunol Inflamm 2004 12 3 169 192 10.1080/092739490500192 15385194 (Pubitemid 39424881)
22. Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection. Nan K, Sun S, Li Y, Qu J, Li G, Luo L, Chen H, Cheng L, Br J Ophthalmol 2010 94 5 654 658 10.1136/bjo.2009.172106 20447969
23. Orbital floor triamcinolone acetonide injections for the management of active non-infectious uveitis. Roesel M, Gutfleisch M, Heinz C, Heimes B, Zurek-Imhoff B, Heiligenhaus A, Eye (Lond) 2009 23 4 910 914 10.1038/eye.2008.114
24. Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. Byun YS, Park YH, J Ocul Pharmacol Ther 2009 25 2 159 162 10.1089/jop.2008.0087 19284323
25. Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Roesel M, Gutfleisch M, Heinz C, Heimes B, Zurek-Imhoff B, Heiligenhaus A, Ophthalmic Res 2009 42 2 81 86 10.1159/000220600 19478546
26. Orbital floor steroid injections in the treatment of uveitis. Riordan-Eva P, Lightman S, Eye (Lond) 1994 8 Pt 1 66 69 (Pubitemid 24141230)
27. Intravitreal dexamethasone effectively reduces postoperative inflammation after vitreoretinal surgery. Chalam KV, Malkani S, Shah VA, Ophthalmic Surg Lasers Imaging 2003 34 3 188 192 12757090 (Pubitemid 36717590)
28. Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Gan IM, Ugahary LC, van Dissel JT, Feron E, Peperkamp E, Veckeneer M, Mulder PG, Platenkamp GJ, van Meurs JC, Graefes Arch Clin Exp Ophthalmol 2005 243 12 1200 1205 10.1007/s00417-005-0133-1 16235062 (Pubitemid 43055182)
29. Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema. Sallam A, Taylor SR, Habot-Wilner Z, Elgohary M, Do HH, McCluskey P, Lightman S, Acta Ophthalmol 2012 90 4 323 e325 10.1111/j.1755-3768.2011.02247.x 21914149
30. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y, Am J Ophthalmol 2004 138 6 1046 1048 10.1016/j.ajo.2004.05.028 15629301 (Pubitemid 40040025)
31. The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. van Kooij B, Rothova A, de Vries P, Ocul Immunol Inflamm 2006 14 2 73 85 10.1080/09273940500545684 16597536
32. Intravitreal triamcinolone for intraocular inflammation and associated macular edema. Couch SM, Bakri SJ, Clin Ophthalmol 2009 3 41 47 19668543
33. Outcome of intravitreal triamcinolone in uveitis. Kok H, Lau C, Maycock N, McCluskey P, Lightman S, Ophthalmology 2005 112 11 1916 e1911-1917 16171868
34. Intravitreal triamcinolone for persistent cystoid macular oedema in eyes with quiescent uveitis. Maca SM, Abela-Formanek C, Kiss CG, Sacu SG, Benesch T, Barisani-Asenbauer T, Clin Experiment Ophthalmol 2009 37 4 389 396 10.1111/j.1442-9071.2009.02033.x 19594566
35. The use of intraocular corticosteroids. Kiernan DF, Mieler WF, Expert Opin Pharmacother 2009 10 15 2511 2525 10.1517/14656560903160671 19761356
36. Safety profile of intravitreal triamcinolone acetonide. Baath J, Ells AL, Crichton A, Kherani A, Williams RG, J Ocul Pharmacol Ther 2007 23 3 304 310 10.1089/jop.2006.125 17593015 (Pubitemid 46986612)
37. Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Tan DT, Chee SP, Lim L, Lim AS, Ophthalmology 1999 106 2 223 231 10.1016/S0161-6420(99)90060-X 9951469 (Pubitemid 30191616)
38. Phase II results of an intraocular steroid delivery system for cataract surgery. Chang DF, Garcia IH, Hunkeler JD, Minas T, Ophthalmology 1999 106 6 1172 1177 10.1016/S0161-6420(99)90262-2 10366088 (Pubitemid 30191522)
39. Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye. Tan DT, Chee SP, Lim L, Theng J, Van Ede M, Ophthalmology 2001 108 12 2172 2181 10.1016/S0161-6420(01)00839-9 11733254 (Pubitemid 33096927)
40. Effect of the macromolecular architecture of biodegradable polyurethanes on the controlled delivery of ocular drugs. da Silva GR, da Silva Cunha A Jr, Ayres E, Orefice RL, J Mater Sci Mater Med 2009 20 2 481 487 10.1007/s10856-008-3607-y 18853235
41. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM, Ozurdex HSG, Arch Ophthalmol 2011 129 5 545 553 10.1001/archophthalmol.2010.339 21220619
42. Dexamethasone implant in pediatric uveitis. Taylor SR, Tomkins-Netzer O, Joshi L, Morarji J, McLoone E, Lightman S, Ophthalmology 2012 119 11 2412 2412 e2412 10.1016/j.ophtha.2012.07.025 23122465
43. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. Driot JY, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA, J Ocul Pharmacol Ther 2004 20 3 269 275 10.1089/1080768041223611 15279731 (Pubitemid 38849806)
44. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. Mruthyunjaya P, Khalatbari D, Yang P, Stinnett S, Tano R, Ashton P, Guo H, Nazzaro M, Jaffe GJ, Arch Ophthalmol 2006 124 7 1012 1018 10.1001/archopht.124.7.1012 16832025 (Pubitemid 44036324)
45. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T, Ophthalmology 2006 113 6 1020 1027 10.1016/j.ophtha.2006.02.021 16690128 (Pubitemid 43795240)
46. Cytomegalovirus endotheliitis after fluocinolone acetonide (Retisert) implant in a patient with Behcet uveitis. Park UC, Kim SJ, Yu HG, Ocul Immunol Inflamm 2011 19 4 282 283 10.3109/09273948.2011.580075 21770807
47. Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma. Malone PE, Herndon LW, Muir KW, Jaffe GJ, Am J Ophthalmol 2010 149 5 800 806 e801 10.1016/j.ajo.2009.12.009 20189158
48. Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis. Chieh JJ, Carlson AN, Jaffe GJ, Am J Ophthalmol 2008 146 4 589 594 10.1016/j.ajo.2008.05.035 18639220
49. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE, Multicenter Uveitis Steroid Treatment Trial Research G, Ophthalmology 2011 118 10 1916 1926 10.1016/j.ophtha.2011.07.027 21840602
50. Iluvien: a new sustained delivery technology for posterior eye disease. Kane FE, Burdan J, Cutino A, Green KE, Expert Opin Drug Deliv 2008 5 9 1039 1046 10.1517/17425247.5.9.1039 18754752
51. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, Busquets M, Ciulla T, Feiner L, Sabates N, Billman K, et al. Ophthalmology 2010 117 7 1393 1399 10.1016/j.ophtha.2009.11.024 20202684
52. Mathematical modeling of triamcinolone acetonide drug release from the I-vation intravitreal implant (a controlled release platform). Barnett PJ, Conf Proc IEEE Eng Med Biol Soc 2009 2009 3087 3090 19963793
53. Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Rabiah PK, Fiscella RG, Tessler HH, Invest Ophthalmol Vis Sci 1996 37 4 613 618 8595961 (Pubitemid 26077681)
54. Intravitreal ketorolac for chronic uveitis and macular edema: a pilot study. Kim SJ, Doherty TJ, Cherney EF, Arch Ophthalmol 2012 130 4 456 460 10.1001/archopthalmol.2011.2627 22491916
55. Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Soheilian M, Karimi S, Ramezani A, Peyman GA, Retina 2010 30 3 509 515 10.1097/IAE.0b013e3181bdfa43 19952986
56. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA, Arch Ophthalmol 1997 115 9 1152 1156 10.1001/archopht.1997.01100160322009 9298056 (Pubitemid 27387951)
57. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, Pe'er J, Ophthalmology 2002 109 9 1709 1716 10.1016/S0161-6420(02)01125-9 12208721 (Pubitemid 35012013)
58. Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Hardwig PW, Pulido JS, Erie JC, Baratz KH, Buettner H, Am J Ophthalmol 2006 142 5 883 885 10.1016/j.ajo.2006.06.002 17056381 (Pubitemid 44584144)
59. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL, Ophthalmology 2009 116 4 797 801 10.1016/j.ophtha.2008.10.033 19344827
60. Intravitreal methotrexate in uveitis. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman S, Ophthalmology 2012 119 4 878 879 22472251
61. Intravitreal methotrexate can induce long-term remission in some patients with non-infectious uveitis. Taylor SR, Banker AJ, Schlaen A, Joshi L, McCluskey P, Lightman S, Retina 2013 In Press
62. Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study. He Y, Liu Y, Liu Y, Wang J, Zhang X, Lu W, Ma Z, Zhu X, Zhang Q, Invest Ophthalmol Vis Sci 2006 47 9 3983 3988 10.1167/iovs.05-1373 16936114 (Pubitemid 46044315)
63. Intravitreal injection of Tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in Rats. Oh-i K, Keino H, Goto H, Yamakawa N, Murase K, Usui Y, Kezuka T, Sakai J, Takeuchi M, Usui M, Br J Ophthalmol 2007 91 2 237 242 10.1136/bjo.2006.103168 16987901 (Pubitemid 46202878)
64. Effects of intravitreal injection of tacrolimus (FK506) in experimental uveitis. Ishikawa T, Hokama H, Katagiri Y, Goto H, Usui M, Curr Eye Res 2005 30 2 93 101 10.1080/02713680490904368 15814467 (Pubitemid 40516085)
65. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Weiss K, Steinbrugger I, Weger M, Ardjomand N, Maier R, Wegscheider BJ, Wedrich A, El-Shabrawi Y, Eye (Lond) 2009 23 9 1812 1818 10.1038/eye.2008.388
66. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Fine HF, Baffi J, Reed GF, Csaky KG, Nussenblatt RB, Am J Ophthalmol 2001 132 5 794 796 10.1016/S0002-9394(01)01103-5 11704050 (Pubitemid 33031303)
67. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ, Cancer Res 2000 60 19 5334 5339 11034066
68. Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. van Kooij B, Rothova A, Rijkers GT, de Groot-Mijnes JD, Am J Ophthalmol 2006 142 1 192 194 10.1016/j.ajo.2006.02.052 16815285 (Pubitemid 43946800)
69. Interleukin 6 induces the expression of vascular endothelial growth factor. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ, J Biol Chem 1996 271 2 736 741 10.1074/jbc.271.2.736 8557680 (Pubitemid 26034921)
70. Intravitreal bevacizumab for treatment of uveitic macular edema. Cordero Coma M, Sobrin L, Onal S, Christen W, Foster CS, Ophthalmology 2007 114 8 1574 1579 e1571 10.1016/j.ophtha.2006.11.028 17363060 (Pubitemid 47126590)
71. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Mackensen F, Heinz C, Becker MD, Heiligenhaus A, Retina 2008 28 1 41 45 10.1097/IAE.0b013e318156db75 18185136
72. Ranibizumab for refractory uveitis-related macular edema. Acharya NR, Hong KC, Lee SM, Am J Ophthalmol 2009 148 2 303 309 e302 10.1016/j.ajo.2009.03. 028 19427988
73. Short-term results of a single intravitreal bevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema. Lasave AF, Zeballos DG, El-Haig WM, Diaz-Llopis M, Salom D, Arevalo JF, Ocul Immunol Inflamm 2009 17 6 423 430 10.3109/09273940903221610 20001264
74. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Bae JH, Lee CS, Lee SC, Retina 2011 31 1 111 118 10.1097/IAE.0b013e3181e378af 20856170
75. Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: a randomized pilot study. Soheilian M, Rabbanikhah Z, Ramezani A, Kiavash V, Yaseri M, Peyman GA, J Ocul Pharmacol Ther 2010 26 2 199 206 10.1089/jop.2009.0093 20307215
76. Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. Cervantes-Castaneda RA, Giuliari GP, Gallagher MJ, Yilmaz T, MacDonell RE, Quinones K, Foster CS, Eur J Ophthalmol 2009 19 4 622 629 19551679
77. Ranibizumab for neovascular age-related macular degeneration. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, N Engl J Med 2006 355 14 1419 1431 10.1056/NEJMoa054481 17021318 (Pubitemid 44511557)
78. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, N Engl J Med 2006 355 14 1432 1444 10.1056/NEJMoa062655 17021319 (Pubitemid 44511558)
79. Infliximab for chronic cystoid macular edema associated with uveitis. Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP, Am J Ophthalmol 2004 138 4 648 650 10.1016/j.ajo.2004.04.066 15488796 (Pubitemid 39420497)
80. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, Markomichelakis N, Ann Intern Med 2004 140 5 404 406 14996689 (Pubitemid 38268925)
81. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN, Lancet 2001 358 9278 295 296 10.1016/S0140-6736(01)05497-6 11498218 (Pubitemid 32738970)
82. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Theodossiadis PG, Markomichelakis NN, Sfikakis PP, Retina 2007 27 4 399 413 10.1097/MAJ. 0b013e3180318fbc 17420690 (Pubitemid 46624278)
83. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Farvardin M, Afarid M, Mehryar M, Hosseini H, Retina 2010 30 9 1530 1535 10.1097/IAE.0b013e3181d3758a 20924267
84. Adverse events after intravitreal infliximab (Remicade). Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N, Retina 2010 30 1 71 80 10.1097/IAE.0b013e3181bcef3b 19996827
85. intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Wu L, Hernandez-Bogantes E, Roca JA, Arevalo JF, Barraza K, Lasave AF, Retina 2011 31 2 298 303 10.1097/IAE.0b013e3181eac7a6 21099452
86. More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial. Pulido JS, Pulido JE, Michet CJ, Vile RG, Retina 2010 30 1 1 5 10.1097/IAE.0b013e3181cde727 20061905
87. Evaluation of potential retinal toxicity of adalimumab (Humira). Tsilimbaris M, Diakonis VF, Naoumidi I, Charisis S, Kritikos I, Chatzithanasis G, Papadaki T, Plainis S, Graefes Arch Clin Exp Ophthalmol 2009 247 8 1119 1125 10.1007/s00417-009-1065-y 19296122
88. Intravitreal adalimumab for refractory uveitis-related macular edema. Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P, Ophthalmology 2010 117 8 1612 1616 10.1016/j.ophtha.2009.12.011 20378179
89. Road to fulfilment: taming the immune response to restore vision. Dick AD, Ophthalmic Res 2012 48 1 43 49 10.1159/000335982 22398563
90. From beach to bedside: history of the development of sirolimus. Napoli KL, Taylor PJ, Ther Drug Monit 2001 23 5 559 586 10.1097/00007691-200110000- 00012 11591905 (Pubitemid 32912281)
91. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Sehgal SN, Clin Biochem 1998 31 5 335 340 10.1016/S0009-9120(98)00045-9 9721431 (Pubitemid 28385231)
92. Interplay between innate and adaptive immunity in the development of non-infectious uveitis. Willermain F, Rosenbaum JT, Bodaghi B, Rosenzweig HL, Childers S, Behrend T, Wildner G, Dick AD, Prog Retin Eye Res 2012 31 2 182 194 10.1016/j.preteyeres.2011.11.004 22120610
93. Understanding uveitis: the impact of research on visual outcomes. de Smet MD, Taylor SR, Bodaghi B, Miserocchi E, Murray PI, Pleyer U, Zierhut M, Barisani-Asenbauer T, LeHoang P, Lightman S, Prog Retin Eye Res 2011 30 6 452 470 10.1016/j.preteyeres.2011.06.005 21807112
94. The danger model: a renewed sense of self. Matzinger P, Science 2002 296 5566 301 305 10.1126/science.1071059 11951032 (Pubitemid 34303674)
95. The NLRP3 inflammasome: a sensor for metabolic danger? Schroder K, Zhou R, Tschopp J, Science 2010 327 5963 296 300 10.1126/science.1184003 20075245
96. Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response. Yu JR, Leslie KS, Current allergy and asthma reports 2011 11 1 12 20 10.1007/s11882-010-0160-9 21104172
97. Ocular neuroprotection by siRNA targeting caspase-2. Ahmed Z, Kalinski H, Berry M, Almasieh M, Ashush H, Slager N, Brafman A, Spivak I, Prasad N, Mett I, et al. Cell death & disease 2011 2 173 10.1038/cddis.2011.54 23926438
98. P2X7 deficiency attenuates renal injury in experimental glomerulonephritis. Taylor SR, Turner CM, Elliott JI, McDaid J, Hewitt R, Smith J, Pickering MC, Whitehouse DL, Cook HT, Burnstock G, et al. J Am Soc Nephrol 2009 20 6 1275 1281 10.1681/ASN.2008060559 19389853
99. SIRT1 activation protects against autoimmune T cell-driven retinal disease in mice via inhibition of IL-2/Stat5 signaling. Gardner PJ, Joshi L, Lee RW, Dick AD, Adamson P, Calder VL, J Autoimmun 2013 42 117 129 23395551
100. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC, Therapeutics, Technology Assessment Subcommittee of the American Academy of N, Neurology 2008 71 10 766 773 10.1212/01.wnl.0000320512.21919.d2 18765653
101. Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease. Raveney BJ, Copland DA, Nicholson LB, Dick AD, Arch Ophthalmol 2008 126 10 1390 1395 10.1001/archopht.126.10.1390 18852417
102. Rituximab in refractory ophthalmic Wegener's granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effective. Joshi L, Lightman SL, Salama AD, Shirodkar AL, Pusey CD, Taylor SR, Ophthalmology 2011 118 12 2498 2503 10.1016/j.ophtha.2011.06.009 21907416
103. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL, Arthritis Rheum 2009 60 5 1540 1547 10.1002/art.24454 19404964
104. Combination intravitreal rituximab and methotrexate for massive subretinal lymphoma. Yeh S, Wilson DJ, Eye (Lond) 2010 24 10 1625 1627 10.1038/eye.2010.111
105. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Furrer E, Berdugo M, Stella C, Behar-Cohen F, Gurny R, Feige U, Lichtlen P, Urech DM, Invest Ophthalmol Vis Sci 2009 50 2 771 778 18757508